Session of 2017

## House Substitute for SENATE BILL No. 51

By Committee on Health and Human Services

3-14

AN ACT concerning controlled substances; the state board of pharmacy; relating to scheduling of controlled substance analogs, controlled substances and new drugs; emergency scheduling; amending K.S.A. 2016 Supp. 21-5701, 65-4101, 65-4102, 65-4105, 65-4107 and 65-4113 and repealing the existing sections.

1 2

Be it enacted by the Legislature of the State of Kansas:

Section 1. K.S.A. 2016 Supp. 21-5701 is hereby amended to read as follows: 21-5701. As used in K.S.A. 2016 Supp. 21-5701 through 21-5717, and amendments thereto: (a) "Controlled substance" means any drug, substance or immediate precursor included in any of the schedules designated in K.S.A. 65-4105, 65-4107, 65-4109, 65-4111 and 65-4113, and amendments thereto.

- (b) (1) "Controlled substance analog" means a substance that is intended for human consumption, and *at least one of the following*:
- (A) The chemical structure of which the substance is substantially similar to the chemical structure of a controlled substance listed in or added to the schedules designated in K.S.A. 65-4105 or 65-4107, and amendments thereto;
- (B) which the substance has a stimulant, depressant or hallucinogenic effect on the central nervous system substantially similar to the stimulant, depressant or hallucinogenic effect on the central nervous system of a controlled substance included in the schedules designated in K.S.A. 65-4105 or 65-4107, and amendments thereto; or
- (C) with respect to a particular individual, which the such individual represents or intends the substance to have a stimulant, depressant or hallucinogenic effect on the central nervous system substantially similar to the stimulant, depressant or hallucinogenic effect on the central nervous system of a controlled substance included in the schedules designated in K.S.A. 65-4105 or 65-4107, and amendments thereto.
  - (2) "Controlled substance analog" does not include:
  - (A) A controlled substance;
- (B) a substance for which there is an approved new drug application; or
- (C) a substance with respect to which an exemption is in effect for investigational use by a particular person under section 505 of the federal

food, drug, and cosmetic act-(, 21 U.S.C. § 355), to the extent conduct with respect to the substance is permitted by the exemption.

- (c) "Cultivate" means the planting or promotion of growth of five or more plants which contain or can produce controlled substances.
- (d) "Distribute" means the actual, constructive or attempted transfer from one person to another of some item whether or not there is an agency relationship. "Distribute" includes, but is not limited to, sale, offer for sale or any act that causes some item to be transferred from one person to another. "Distribute" does not include acts of administering, dispensing or prescribing a controlled substance as authorized by the pharmacy act of the state of Kansas, the uniform controlled substances act or otherwise authorized by law.
  - (e) "Drug" means:
- (1) Substances recognized as drugs in the official United States pharmacopoeia pharmacopeia, official homeopathic pharmacopoeia of the United States or official national formulary or any supplement to any of them:
- (2) substances intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease in man or animals;
- (3) substances, other than food, intended to affect the structure or any function of the body of man or animals; and
- (4) substances intended for use as a component of any article specified in paragraph (1), (2) or (3). It does not include devices or their components, parts or accessories.
- (f) "Drug paraphernalia" means all equipment and materials of any kind which are used, or primarily intended or designed for use in planting, propagating, cultivating, growing, harvesting, manufacturing, compounding, converting, producing, processing, preparing, testing, analyzing, packaging, repackaging, storing, containing, concealing, injecting, ingesting, inhaling or otherwise introducing into the human body a controlled substance and in violation of this act. "Drug paraphernalia" shall include, but is not limited to:
- (1) Kits used or intended for use in planting, propagating, cultivating, growing or harvesting any species of plant which is a controlled substance or from which a controlled substance can be derived:
- (2) kits used or intended for use in manufacturing, compounding, converting, producing, processing or preparing controlled substances;
- (3) isomerization devices used or intended for use in increasing the potency of any species of plant which is a controlled substance;
- (4) testing equipment used or intended for use in identifying or in analyzing the strength, effectiveness or purity of controlled substances;
- (5) scales and balances used or intended for use in weighing or measuring controlled substances;

2

3

4

5

6 7

8

9

10

11

12

13 14

15 16

17

18

19 20

21

22

23

24

25

26 27

28 29

31

32

33

34

36

38

- (6) diluents and adulterants, including, but not limited to, quinine hydrochloride, mannitol, mannite, dextrose and lactose, which are used or intended for use in cutting controlled substances;
- (7) separation gins and sifters used or intended for use in removing twigs and seeds from or otherwise cleaning or refining marijuana;
- (8) blenders, bowls, containers, spoons and mixing devices used or intended for use in compounding controlled substances;
- (9) capsules, balloons, envelopes, bags and other containers used or intended for use in packaging small quantities of controlled substances;
- (10) containers and other objects used or intended for use in storing or concealing controlled substances;
- (11) hypodermic syringes, needles and other objects used or intended for use in parenterally injecting controlled substances into the human body:
- (12) objects used or primarily intended or designed for use in ingesting, inhaling or otherwise introducing marijuana, cocaine, hashish, hashish oil, phencyclidine (PCP), methamphetamine or amphetamine into the human body, such as:
- (A) Metal, wooden, acrylic, glass, stone, plastic or ceramic pipes with or without screens, permanent screens, hashish heads or punctured metal bowls:
- (B) water pipes, bongs or smoking pipes designed to draw smoke through water or another cooling device;
- (C) carburetion pipes, glass or other heat resistant tubes or any other device used-or, intended to be used, or designed to be used to cause vaporization of a controlled substance for inhalation;
  - (D) smoking and carburetion masks;
- (E) roach clips, objects used to hold burning material, such as a marijuana cigarette, that has become too small or too short to be held in 30 the hand:
  - (F) miniature cocaine spoons and cocaine vials:
  - (G) chamber smoking pipes;
  - (H) carburetor smoking pipes;
    - (I) electric smoking pipes;
- (J) air-driven smoking pipes: 35
  - (K) chillums;
- 37 (L) bongs;
  - (M) ice pipes or chillers;
- 39 any smoking pipe manufactured to disguise its intended purpose; (N)
- wired cigarette papers; or 40 (O)
  - cocaine freebase kits. (P)
- "Drug paraphernalia" shall not include any products, chemicals or 42 materials described in subsection (a) of K.S.A. 2016 Supp. 21-5709(a), 43

and amendments thereto.

- (g) "Immediate precursor" means a substance which the *state* board of pharmacy has found to be and by rules and regulations designates as being the principal compound commonly used or produced primarily for use and which is an immediate chemical intermediary used or likely to be used in the manufacture of a controlled substance, the control of which is necessary to prevent, curtail or limit manufacture.
  - (h) "Isomer" means all enantiomers and diastereomers.
- (i) "Manufacture" means the production, preparation, propagation, compounding, conversion or processing of a controlled substance either directly or indirectly or by extraction from substances of natural origin or independently by means of chemical synthesis or by a combination of extraction and chemical synthesis. "Manufacture" does not include:
- (1) The preparation or compounding of a controlled substance by an individual for the individual's own lawful use or the preparation, compounding, packaging or labeling of a controlled substance:
- (A) By a practitioner or the practitioner's agent pursuant to a lawful order of a practitioner as an incident to the practitioner's administering or dispensing of a controlled substance in the course of the practitioner's professional practice; or
- (B) by a practitioner or by the practitioner's authorized agent under such practitioner's supervision for the purpose of or as an incident to research, teaching or chemical analysis or by a pharmacist or medical care facility as an incident to dispensing of a controlled substance; or
- (2) the addition of diluents or adulterants, including, but not limited to, quinine hydrochloride, mannitol, mannite, dextrose or lactose, which are intended for use in cutting a controlled substance.
- (j) "Marijuana" means all parts of all varieties of the plant Cannabis whether growing or not, the seeds thereof, the resin extracted from any part of the plant and every compound, manufacture, salt, derivative, mixture or preparation of the plant, its seeds or resin. "Marijuana" does not include the mature stalks of the plant, fiber produced from the stalks, oil or cake made from the seeds of the plant, any other compound, manufacture, salt, derivative, mixture or preparation of the mature stalks, except the resin extracted therefrom, fiber, oil or cake or the sterilized seed of the plant which is incapable of germination.
  - (k) "Minor" means a person under 18 years of age.
- (l) "Narcotic drug" means any of the following whether produced directly or indirectly by extraction from substances of vegetable origin or independently by means of chemical synthesis or by a combination of extraction and chemical synthesis:
- (1) Opium and opiate and any salt, compound, derivative or preparation of opium or opiate;

- (2) any salt, compound, isomer, derivative or preparation thereof which is chemically equivalent or identical with any of the substances referred to in paragraph (1) but not including the isoquinoline alkaloids of opium;
  - (3) opium poppy and poppy straw;
- (4) coca leaves and any salt, compound, derivative or preparation of coca leaves and any salt, compound, isomer, derivative or preparation thereof which is chemically equivalent or identical with any of these substances, but not including decocainized coca leaves or extractions of coca leaves which do not contain cocaine or ecgonine.
- (m) "Opiate" means any substance having an addiction-forming or addiction-sustaining liability similar to morphine or being capable of conversion into a drug having addiction-forming or addiction-sustaining liability. "Opiate" does not include, unless specifically designated as controlled under K.S.A. 65-4102, and amendments thereto, the dextrorotatory isomer of 3-methoxy-n-methylmorphinan and its salts (dextromethorphan). "Opiate" does include its racemic and levorotatory forms.
- (n) "Opium poppy" means the plant of the species Papaver somniferum l. except its seeds.
- (o) "Person" means individual, corporation, government or governmental subdivision or agency, business trust, estate, trust, partnership, association or any other legal entity.
- (p) "Poppy straw" means all parts, except the seeds, of the opium poppy, after mowing.
- (q) "Possession" means having joint or exclusive control over an item with knowledge of and intent to have such control or knowingly keeping some item in a place where the person has some measure of access and right of control.
- (r) "School property" means property upon which is located a structure used by a unified school district or an accredited nonpublic school for student instruction or attendance or extracurricular activities of pupils enrolled in kindergarten or any of the grades one through 12. This definition shall not be construed as requiring that school be in session or that classes are actually being held at the time of the offense or that children must be present within the structure or on the property during the time of any alleged criminal act. If the structure or property meets the above definition, the actual use of that structure or property at the time alleged shall not be a defense to the crime charged or the sentence imposed.
- (s) "Simulated controlled substance" means any product which identifies itself by a common name or slang term associated with a controlled substance and which indicates on its label or accompanying

promotional material that the product simulates the effect of a controlled substance.

- Sec. 2. K.S.A. 2016 Supp. 65-4101 is hereby amended to read as follows: 65-4101. As used in this act: (a) "Administer" means the direct application of a controlled substance, whether by injection, inhalation, ingestion or any other means, to the body of a patient or research subject by:
- (1) A practitioner or pursuant to the lawful direction of a practitioner; or
- (2) the patient or research subject at the direction and in the presence of the practitioner.
  - (b) "Agent" means an authorized person who acts on behalf of or at the direction of a manufacturer, distributor or dispenser. It does not include a common carrier, public warehouseman or employee of the carrier or warehouseman.
  - (c) "Application service provider" means an entity that sells electronic prescription or pharmacy prescription applications as a hosted service where the entity controls access to the application and maintains the software and records on its server.
    - (d) "Board" means the state board of pharmacy.
- (e) "Bureau" means the bureau of narcotics and dangerous drugs, United States department of justice, or its successor agency.
- (f) "Controlled substance" means any drug, substance or immediate precursor included in any of the schedules designated in K.S.A. 65-4105, 65-4107, 65-4109, 65-4111 and 65-4113, and amendments thereto.
- (g) (1) "Controlled substance analog" means a substance that is intended for human consumption, and *at least one of the following*:
- (A) The chemical structure of which the substance is substantially similar to the chemical structure of a controlled substance listed in or added to the schedules designated in K.S.A. 65-4105 or 65-4107, and amendments thereto;
- (B) which the substance has a stimulant, depressant or hallucinogenic effect on the central nervous system substantially similar to the stimulant, depressant or hallucinogenic effect on the central nervous system of a controlled substance included in the schedules designated in K.S.A. 65-4105 or 65-4107, and amendments thereto; or
- (C) with respect to a particular individual,—which such individual represents or intends *the substance* to have a stimulant, depressant or hallucinogenic effect on the central nervous system substantially similar to the stimulant, depressant or hallucinogenic effect on the central nervous system of a controlled substance included in the schedules designated in K.S.A. 65-4105 or 65-4107, and amendments thereto.
  - (2) "Controlled substance analog" does not include:

- (A) A controlled substance;
- (B) a substance for which there is an approved new drug application; or
- (C) a substance with respect to which an exemption is in effect for investigational use by a particular person under section 505 of the federal food, drug and cosmetic act, 21 U.S.C. § 355, to the extent conduct with respect to the substance is permitted by the exemption.
- (h) "Counterfeit substance" means a controlled substance which, or the container or labeling of which, without authorization bears the trademark, trade name or other identifying mark, imprint, number or device or any likeness thereof of a manufacturer, distributor or dispenser other than the person who in fact manufactured, distributed or dispensed the substance.
- (i) "Cultivate" means the planting or promotion of growth of five or more plants which contain or can produce controlled substances.
- (j) "DEA" means the U.S. department of justice, drug enforcement administration.
- (k) "Deliver" or "delivery" means the actual, constructive or attempted transfer from one person to another of a controlled substance, whether or not there is an agency relationship.
- (l) "Dispense" means to deliver a controlled substance to an ultimate user or research subject by or pursuant to the lawful order of a practitioner, including the packaging, labeling or compounding necessary to prepare the substance for that delivery, or pursuant to the prescription of a mid-level practitioner.
- (m) "Dispenser" means a practitioner or pharmacist who dispenses, or a physician assistant who has authority to dispense prescription-only drugs in accordance with K.S.A. 65-28a08(b), and amendments thereto.
- (n) "Distribute" means to deliver other than by administering or dispensing a controlled substance.
  - (o) "Distributor" means a person who distributes.
- (p) "Drug" means: (1) Substances recognized as drugs in the official United States—pharmacopoeia pharmacopeia, official homeopathic pharmacopoeia of the United States or official national formulary or any supplement to any of them; (2) substances intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease in human or animals; (3) substances (other than food) intended to affect the structure or any function of the body of human or animals; and (4) substances intended for use as a component of any article specified in paragraph (1), (2) or (3). It does not include devices or their components, parts or accessories.
- (q) "Immediate precursor" means a substance which the board has found to be and by rule and regulation designates as being the principal compound commonly used or produced primarily for use and which is an

immediate chemical intermediary used or likely to be used in the manufacture of a controlled substance, the control of which is necessary to prevent, curtail or limit manufacture.

- (r) "Electronic prescription" means an electronically prepared prescription that is authorized and transmitted from the prescriber to the pharmacy by means of electronic transmission.
- (s) "Electronic prescription application" means software that is used to create electronic prescriptions and that is intended to be installed on the prescriber's computers and servers where access and records are controlled by the prescriber.
- (t) "Electronic signature" means a confidential personalized digital key, code, number or other method for secure electronic data transmissions which identifies a particular person as the source of the message, authenticates the signatory of the message and indicates the person's approval of the information contained in the transmission.
- (u) "Electronic transmission" means the transmission of an electronic prescription, formatted as an electronic data file, from a prescriber's electronic prescription application to a pharmacy's computer, where the data file is imported into the pharmacy prescription application.
- (v) "Electronically prepared prescription" means a prescription that is generated using an electronic prescription application.
- (w) "Facsimile transmission" or "fax transmission" means the transmission of a digital image of a prescription from the prescriber or the prescriber's agent to the pharmacy. "Facsimile transmission" includes, but is not limited to, transmission of a written prescription between the prescriber's fax machine and the pharmacy's fax machine; transmission of an electronically prepared prescription from the prescriber's electronic prescription application to the pharmacy's fax machine, computer or printer; or transmission of an electronically prepared prescription from the prescriber's fax machine to the pharmacy's fax machine, computer or printer.
- (x) "Intermediary" means any technology system that receives and transmits an electronic prescription between the prescriber and the pharmacy.
  - (y) "Isomer" means all enantiomers and diastereomers.
- (z) "Manufacture" means the production, preparation, propagation, compounding, conversion or processing of a controlled substance either directly or indirectly or by extraction from substances of natural origin or independently by means of chemical synthesis or by a combination of extraction and chemical synthesis and includes any packaging or repackaging of the substance or labeling or relabeling of its container, except that this term does not include the preparation or compounding of a controlled substance by an individual for the individual's own lawful use

or the preparation, compounding, packaging or labeling of a controlled substance:

- (1) By a practitioner or the practitioner's agent pursuant to a lawful order of a practitioner as an incident to the practitioner's administering or dispensing of a controlled substance in the course of the practitioner's professional practice; or
- (2) by a practitioner or by the practitioner's authorized agent under such practitioner's supervision for the purpose of or as an incident to research, teaching or chemical analysis or by a pharmacist or medical care facility as an incident to dispensing of a controlled substance.
- (aa) "Marijuana" means all parts of all varieties of the plant Cannabis whether growing or not, the seeds thereof, the resin extracted from any part of the plant and every compound, manufacture, salt, derivative, mixture or preparation of the plant, its seeds or resin. It does not include the mature stalks of the plant, fiber produced from the stalks, oil or cake made from the seeds of the plant, any other compound, manufacture, salt, derivative, mixture or preparation of the mature stalks, except the resin extracted therefrom, fiber, oil, or cake or the sterilized seed of the plant which is incapable of germination.
- (bb) "Medical care facility" shall have the meaning ascribed to that term in K.S.A. 65-425, and amendments thereto.
- (cc) "Mid-level practitioner" means a certified nurse-midwife engaging in the independent practice of midwifery under the independent practice of midwifery act, an advanced practice registered nurse issued a license pursuant to K.S.A. 65-1131, and amendments thereto, who has authority to prescribe drugs pursuant to a written protocol with a responsible physician under K.S.A. 65-1130, and amendments thereto, or a physician assistant licensed under the physician assistant licensure act who has authority to prescribe drugs pursuant to a written agreement with a supervising physician under K.S.A. 65-28a08, and amendments thereto.
- (dd) "Narcotic drug" means any of the following whether produced directly or indirectly by extraction from substances of vegetable origin or independently by means of chemical synthesis or by a combination of extraction and chemical synthesis:
- (1) Opium and opiate and any salt, compound, derivative or preparation of opium or opiate;
- (2) any salt, compound, isomer, derivative or preparation thereof which is chemically equivalent or identical with any of the substances referred to in paragraph (1) but not including the isoquinoline alkaloids of opium;
  - (3) opium poppy and poppy straw;
- (4) coca leaves and any salt, compound, derivative or preparation of coca leaves, and any salt, compound, isomer, derivative or preparation

thereof which is chemically equivalent or identical with any of these substances, but not including decocainized coca leaves or extractions of coca leaves which do not contain cocaine or ecgonine.

- (ee) "Opiate" means any substance having an addiction-forming or addiction-sustaining liability similar to morphine or being capable of conversion into a drug having addiction-forming or addiction-sustaining liability. It does not include, unless specifically designated as controlled under K.S.A. 65-4102, and amendments thereto, the dextrorotatory isomer of 3-methoxy-n-methylmorphinan and its salts (dextromethorphan). It does include its racemic and levorotatory forms.
- (ff) "Opium poppy" means the plant of the species Papaver somniferum l. except its seeds.
- (gg) "Person" means an individual, corporation, government, or governmental subdivision or agency, business trust, estate, trust, partnership or association or any other legal entity.
- (hh) "Pharmacist" means any natural person licensed under K.S.A. 65-1625 et seq., and amendments thereto, to practice pharmacy.
- (ii) "Pharmacist intern" means: (1) A student currently enrolled in an accredited pharmacy program; (2) a graduate of an accredited pharmacy program serving such person's internship; or (3) a graduate of a pharmacy program located outside of the United States which is not accredited and who had successfully passed equivalency examinations approved by the board.
- (jj) "Pharmacy prescription application" means software that is used to process prescription information, is installed on a pharmacy's computers and servers, and is controlled by the pharmacy.
- (kk) "Poppy straw" means all parts, except the seeds, of the opium poppy, after mowing.
- (II) "Practitioner" means a person licensed to practice medicine and surgery, dentist, podiatrist, veterinarian, optometrist, or scientific investigator or other person authorized by law to use a controlled substance in teaching or chemical analysis or to conduct research with respect to a controlled substance.
  - (mm) "Prescriber" means a practitioner or a mid-level practitioner.
- (nn) "Production" includes the manufacture, planting, cultivation, growing or harvesting of a controlled substance.
- (oo) "Readily retrievable" means that records kept by automatic data processing applications or other electronic or mechanized recordkeeping systems can be separated out from all other records within a reasonable time not to exceed 48 hours of a request from the board or other authorized agent or that hard-copy records are kept on which certain items are asterisked, redlined or in some other manner visually identifiable apart from other items appearing on the records.

- (pp) "Ultimate user" means a person who lawfully possesses a controlled substance for such person's own use or for the use of a member of such person's household or for administering to an animal owned by such person or by a member of such person's household.
- Sec. 3. K.S.A. 2016 Supp. 65-4102 is hereby amended to read as follows: 65-4102. (a) The board shall administer this act and may adopt rules and regulations relating to the registration and control of the manufacture, distribution and dispensing of controlled substances within this state. All rules and regulations of the board shall be adopted in conformance with article 4 of chapter 77 of the Kansas Statutes Annotated, and amendments thereto, and the procedures prescribed by this act.
- (b) Annually, the board shall submit to the speaker of the house of representatives and the president of the senate a report on substances proposed by the board for scheduling, rescheduling or deletion by the legislature with respect to any one of the schedules as set forth in this act, and reasons for the proposal shall be submitted by the board therewith and a report of the substances scheduled during the preceding calendar year under subsection (e), if any, along with the reasons for the proposal and the scheduling. In making a determination regarding the proposal to schedule, reschedule or delete a substance, the board shall consider the following:
  - (1) The actual or relative potential for abuse;
  - (2) the scientific evidence of its pharmacological effect, if known;
  - (3) the state of current scientific knowledge regarding the substance;
  - (4) the history and current pattern of abuse;
  - (5) the scope, duration and significance of abuse;
  - (6) the risk to the public health;
- (7) the potential of the substance to produce psychological or physiological dependence liability; and
- (8) whether the substance is an immediate precursor of a substance already controlled under this article.
- (c) The board shall not include any nonnarcotic substance within a schedule if such substance may be lawfully sold over the counter without a prescription under the federal food, drug and cosmetic act.
- (d) Authority to control under this section does not extend to distilled spirits, wine, malt beverages or tobacco.
- (e) (1) Upon receipt of notice under K.S.A. 2016 Supp. 21-5715, and amendments thereto, or upon the board's finding of an imminent hazard to the public safety, the board shall initiate scheduling of the controlled substance analog or a new drug, as defined in this subsection, on an emergency basis pursuant to this subsection. The scheduling of a substance under this subsection expires-one year on July 1 of the following calendar year after the adoption of the scheduling rule and regulation.

- (2) With respect to the finding of an imminent hazard to the public safety, the board shall consider whether the substance has been scheduled on a temporary basis under federal law or factors set forth in subsections (b)(4), (5) and (6), and may also consider clandestine importation, manufacture or distribution, and if available, information concerning the other factors set forth in subsection (b).
- (3) A rule and regulation may not be adopted under this subsection until the board initiates a rulemaking proceeding under subsection (a) with respect to the substance. A rule adopted under this subsection lapses upon the conclusion of the rulemaking proceeding initiated under subsection (a) with respect to the substance. A rule and regulation adopted under this subsection shall expire on July 1 of the calendar year following the year of its adoption.
- (4) As used in this subsection, "new drug" means: (A) Any drug the composition of which is such that such drug is not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, as safe and effective for use under the conditions prescribed, recommended or suggested in the labeling thereof; or (B) any drug the composition of which is such that such drug, as a result of investigations to determine its safety and effectiveness for use under such conditions, has become so recognized, but that has not, other than in such investigations, been used to a material extent or for a material time under such conditions. The term "new drug" shall not include amygdalin (laetrile).
- Sec. 4. K.S.A. 2016 Supp. 65-4105 is hereby amended to read as follows: 65-4105. (a) The controlled substances listed in this section are included in schedule I and the number set forth opposite each drug or substance is the DEA controlled substances code which has been assigned to it.
- (b) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation:
- (1) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-Nphenylacetamide)......9821 Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-(2) Acetylmethadol......9601 (3) AH-7921 (3.4-dichloro-N-[(1-(4) dimethylaminocyclohexylmethyl]benzamide)......9551 Allylprodine......9602 (4)(5)Alphacetylmethadol......9603 (5)(6)(except levo-alphacetylmethadol also known as levo-alpha-

1		acetylmethadol, levomethadyl acetate or LAAM)	
2	<del>(6)</del> (7)	Alphameprodine	9604
3	<del>(7)</del> (8)	Alphamethadol	9605
4	<del>(8)</del> (9)	Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)	ethyl)
5		4-piperidyl] propionanilide; 1-(1-methyl-2-phenylethyl)	-4-(N-
6		propanilido) piperidine)	
7	<del>(9)</del> (10)	Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)eth	ıyl-4-
8		piperidinyl]-N-phenylpropanamide)	
9	<del>(10)</del> (11)	Benzethidine	9606
10	<del>(11)</del> (12)	Betacetylmethadol	9607
11	<del>(12)</del> (13)	Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4	_
12		piperidinyl]-N-phenylpropanamide)	
13	(13)(14)	Beta-hydroxy-3-methylfentanyl (other name: N-[1-(2-hy	ydroxy-
14		2-phenethyl)-3-methyl-4-piperidinyl]-N-	
15		phenylpropanamide)	
16	(15)	Beta-hydroxythiofentanyl (N-[1-[2-hydroxy-2-(thiophen	
17		yl)ethyl]piperidin-4-yl]-N-phenylpropionamide)	
18	<del>(14)</del> (16)	Betameprodine	
19	<del>(15)</del> (17)	Betamethadol	
20	<del>(16)</del> (18)	Betaprodine	9611
21	(19)	Butyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-	
22		phenylbutyramide)	
23	(17)(20)	Clonitazene	
24	<del>(18)</del> (21)	Dextromoramide	
25	<del>(19)</del> (22)	Diampromide	
26	<del>(20)</del> (23)	Diethylthiambutene	
27	<del>(21)</del> (24)	Difenoxin	
28	<del>(22)</del> (25)	Dimenoxadol	
29	$\frac{(23)}{(26)}$	Dimepheptanol	
30	<del>(24)</del> (27)	Dimethylthiambutene	
31	<del>(25)</del> (28)	Dioxaphetyl butyrate	
32	<del>(26)</del> (29)	Dipipanone	
33	<del>(27)</del> (30)	Ethylmethylthiambutene	
34	<del>(28)</del> (31)	Etonitazene	
35	<del>(29)</del> (32)	Etoxeridine	9625
36	(33)	Furanyl fentanyl N-(1-phenethylpiperidin-4-yl)-N-	
37		phenylfuran-2-carboxamide	
38	<del>(30)</del> (34)	Furethidine	
39	<del>(31)</del> (35)	Hydroxypethidine	
40	<del>(32)</del> (36)	Ketobemidone	
41	<del>(33)</del> (37)	Levomoramide	
42	<del>(34)</del> (38)	Levophenacylmorphan	
43	(35)(39)	3-Methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4-pip	eridvl1-

1		N-phenylpropanamide)	
2	<del>(36)</del> (40)	3-Methylthiofentanyl (N-[(3-methyl-1-(2-thienyl)ethyl-4-	
3		piperidinyl]-N-phenylpropanamide)	9833
4	<del>(37)</del> (41)	Morpheridine	
5	(42)	O-desmethyltramadol Some trade or other names: 2-	
6		((dimethylamino)methyl-1-(3- hydroxyphenyl)cyclohexan	
7		3-(2-((dimethylamino)methyl)-1-hydroxycyclohexyl)pheno	
8	<del>(38)</del> (43)	MPPP (1-methyl-4-phenyl-4-propionoxypiperidine)	
9	<del>(39)</del> (44)	Noracymethadol	
10	<del>(40)</del> (45)	Norlevorphanol	
11	<del>(41)</del> (46)	Normethadone	
12	<del>(42)</del> (47)	Norpipanone	9636
13	<del>(43)</del> (48)	Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-	
14		(2-phenethyl)-4-piperidinyl]propanamide)	
15	<del>(44)</del> (49)	PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine).	
16	<del>(45)</del> (50)	Phenadoxone	
17	<del>(46)</del> (51)	Phenampromide	
18	<del>(47)</del> (52)	Phenomorphan	
19	<del>(48)</del> (53)	Phenoperidine	
20	<del>(49)</del> (54)	Piritramide	
21	<del>(50)</del> (55)	Proheptazine	
22	<del>(51)</del> (56)	Properidine	
23	<del>(52)</del> (57)	Propiram	
24	<del>(53)</del> (58)	Racemoramide	9645
25	<del>(54)</del> (59)	Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-	
26		piperidinyl]-propanamide)	
27	<del>(55)</del> (60)	Tilidine	
28	<del>(56)</del> (61)	Trimeperidine	
29	(62)	U-47700 (3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]	-
30		N-methylbenzamide)	
31		Any of the following opium derivatives, their salts, isome	
32		somers, unless specifically excepted, whenever the existe	
33		ts, isomers and salts of isomers is possible within the s	pecific
34		designation:	
35	(1)	Acetorphine	
36	(2)	Acetyldihydrocodeine	
37	(3)	Benzylmorphine	
38	(4)	Codeine methylbromide	
39	(5)	Codeine-N-Oxide	
40	(6)	Cyprenorphine	
41	(7)	Desomorphine	
42	(8)	Dihydromorphine	9145
43	(9)	Drotebanol	9335

1	(10)	Etorphine (except hydrochloride salt)	9056
2	(11)	Heroin	9200
3	(12)	Hydromorphinol	9301
4	(13)	Methyldesorphine	9302
5	(14)	Methyldihydromorphine	9304
6	(15)	Morphine methylbromide	9305
7	(16)	Morphine methylsulfonate	9306
8	(17)	Morphine-N-Oxide	9307
9	(18)	Myrophine	9308
10	(19)	Nicocodeine	9309
11	(20)	Nicomorphine	9312
12	(21)	Normorphine	9313
13	(22)	Pholcodine	9314
14	(23)	Thebacon	9315
15	(d)	Any material, compound, mixture or preparation which	contains
16	any qua	antity of the following hallucinogenic substances, the	ir salts,
17	isomers	and salts of isomers, unless specifically excepted, when	ever the
18	existence	e of these salts, isomers and salts of isomers is possible w	ithin the
19	specific	chemical designation:	
20	(1)	Alpha-ethyltryptamine 7249 Some trade or other names.	:
21		etryptamine; Monase; α-ethyl-1H-indole-3-ethanamine;	3-
22		(2-aminobutyl) indole; $\alpha$ -ET; and AET.	
23	(2)	4-bromo-2,5-dimethoxy-amphetamine	
24		Some trade or other names: 4-bromo-2,5-dimethoxy-alp	ha-
25		methylphenethylamine; 4-bromo-2,5-DMA.	
26	<del>(2)</del> (3)	2,5-dimethoxyamphetamine	7396
27		Some trade or other names: 2,5-dimethoxy-alpha-methy	1-
28		phenethylamine; 2,5-DMA.	
29	(3)(4)	4-methoxyamphetamine	
30		Some trade or other names: 4-methoxy-alpha-methylphe	ene-
31		thylamine; paramethoxyamphetamine; PMA.	
32	(4)(5)	5-methoxy-3,4-methylenedioxy-amphetamine	7401
33	<del>(5)</del> (6)	4-methyl-2,5-dimethoxy-amphetamine	7395
34		Some trade or other names: 4-methyl-2,5-dimethoxy-alp	ha-
35		methylphenethylamine; "DOM"; and "STP".	
36	<del>(6)</del> (7)	3,4-methylenedioxy amphetamine	
37	<del>(7)</del> (8)	3,4-methylenedioxymethamphetamine (MDMA)	
38	<del>(8)</del> (9)	3,4-methylenedioxy-N-ethylamphetamine (also known a	
39		N-ethyl-alpha-methyl-3,4 (methylenedioxy) phenethylar	
40		N-ethyl MDA, MDE, and MDEA)	
41	<del>(9)</del> (10)	N-hydroxy-3,4-methylenedioxyamphetamine (also know	vn
42		as N-hydroxy-alpha-methyl-3,4-(methylenedioxy)	
43		phenethylamine, and N-hydroxy MDA)	7402

1	<del>(10)</del> (11)	3,4,5-trimethoxy amphetamine	7390
2	$\frac{(11)}{(12)}$	Bufotenine	
3		Some trade or other names: 3-(Beta-Dimethylaminoethyl)-	
4		5-hydroxyindole; 3-(2-dimethylaminoethyl)-5-indolol; N,	
5		N-dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine;	
6		mappine.	
7	$\frac{(12)}{(13)}$	Diethyltryptamine	7434
8	( )( )	Some trade or other names: N,N-Diethyltryptamine; DET.	
9	$\frac{(13)}{(14)}$	Dimethyltryptamine	7435
10	( )( )	Some trade or other names: DMT.	
11	<del>(14)</del> (15)	Ibogaine	7260
12	( )( )	Some trade or other names: 7-Ethyl-6,6 Beta,7,8,9,10,12,13	
13		octahydro-2-methoxy-6,9-methano -5H-pyrido[1',2':1,2]	
14		azepino [5,4-b]indole; Tabernanthe iboga	
15	<del>(15)</del> (16)	Lysergic acid diethylamide	7315
16	<del>(16)</del> (17)	Marijuana	7360
17	<del>(17)</del> (18)	Mescaline	
18	<del>(18)</del> (19)	Parahexyl	
19	( )( )	Some trade or other names: 3-Hexyl-l-hydroxy-7,8,9,10-	
20		tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran; Synhexy	1.
21	(19)(20)	Peyote	
22	, , , ,	Meaning all parts of the plant presently classified botanical	
23		as Lophophora williamsii Lemaire, whether growing or	-
24		not, the seeds thereof, any extract from any part of such pla	nt,
25		and every compound, manufacture, salts, derivative, mixtur	e
26		or preparation of such plant, its seeds or extracts.	
27	<del>(20)</del> (21)	N-ethyl-3-piperidyl benzilate	7482
28	<del>(21)</del> (22)	N-methyl-3-piperidyl benzilate	7484
29	$\frac{(22)}{(23)}$	Psilocybin	7437
30	$\frac{(23)}{(24)}$	Psilocyn	7438
31		Some trade or other names: Psilocin.	
32	$\frac{(24)}{(25)}$	Ethylamine analog of phencyclidine	7455
33		Some trade or other names: N-ethyl-1-phenyl-cyclo-	
34		hexylamine; (1-phenylcyclohexyl)ethylamine; N-(1-	
35		phenylcyclohexyl)ethylamine; cyclohexamine; PCE.	
36	$\frac{(25)}{(26)}$	Pyrrolidine analog of phencyclidine	7458
37		Some trade or other names: 1-(1-phenylcyclohexyl)-	
38		pyrrolidine; PCPy; PHP.	
39	<del>(26)</del> (27)	Thiophene analog of phencyclidine	7470
40		Some trade or other names: 1-[1-(2-thienyl)-cyclohexyl]-	
41		piperidine; 2-thienyl analog of phencyclidine; TPCP; TCP.	
42	<del>(27)</del> (28)	1-[1-(2-thienyl)-cyclohexyl] pyrrolidine	7473
43		Some other names: TCPv.	

1	<del>(28)</del> (29)	2,5-dimethoxy-4-ethylamphetamine7399
2		Some trade or other names: DOET.
3	<del>(29)</del> (30)	Salvia divinorum or salvinorum A; all parts of the plant
4		presently classified botanically as salvia divinorum, whether
5		growing or not, the seeds thereof, any extract from any part of
6		such plant, and every compound, manufacture, salts, derivative,
7		mixture or preparation of such plant, its seeds or extracts.
8	(30)(31)	Datura stramonium, commonly known as gypsum weed or
9		jimson weed; all parts of the plant presently classified
10		botanically as datura stramonium, whether growing or not, the
11		seeds thereof, any extract from any part of such plant, and every
12		compound, manufacture, salts, derivative, mixture or
13		preparation of such plant, its seeds or extracts.
14	<del>(31)</del> (32)	N-benzylpiperazine
15		Some trade or other names: BZP.
16	<del>(32)</del> (33)	1-(3-[trifluoromethylphenyl])piperazine
17		Some trade or other names: TFMPP.
18	<del>(33)</del> (34)	4-Bromo-2,5-dimethoxyphenethylamine7392
19	<del>(34)</del> <i>(35)</i>	2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7),
20		its optical isomers, salts and salts of optical isomers7348
21	<del>(35)</del> (36)	Alpha-methyltryptamine (other name: AMT)7432
22	<del>(36)</del> (37)	5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT), its
23		isomers, salts and salts of isomers7439
24	<del>(37)</del> (38)	2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E)7509
25	<del>(38)</del> (39)	2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D)7508
26	<del>(39)</del> (40)	2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C)7519
27	<del>(40)</del> (41)	2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I)7518
28	<del>(41)</del> (42)	2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine
29		(2C-T-2)
30	<del>(42)</del> (43)	2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine
31		(2C-T-4)
32	<del>(43)</del> (44)	2-(2,5-Dimethoxyphenyl)ethanamine (2C-H)7517
33	<del>(44)</del> (45)	2-(2,5-Dimethoxy-4-nitrophenyl)ethanamine (2C-N)7521
34	<del>(45)</del> (46)	2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P)7524
35	<del>(46)</del> (47)	5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT)7431
36		Some trade or other names: 5-methoxy-3-[2-(dimethylamino)
37		ethyl]indole.
38	<del>(47)</del> (48)	2–(4–iodo–2,5–dimethoxyphenyl)–N–(2–methoxybenzyl)
39		ethanamine
10		Some trade or other names: 25I–NBOMe; 2C–I–NBOMe; 25I;
41		Cimbi-5.
12	<del>(48)</del> (49)	2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)
13		ethanamine7537

1		Some trade or other names: 25C–NBOMe; 2C–C–NBOMe;
2		25C; Cimbi–82.
3	(49)(50)	2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-
4		methoxybenzyl)ethanamine
5		Some trade or other names: 25B–NBOMe; 2C–B–NBOMe;
6		25B; Cimbi–36.
7	(50)(51)	2-(2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
8		Some trade or other names: 25H-NBOMe.
9	<del>(51)</del> (52)	2-(2,5-dimethoxy-4-methylphenyl)-N-(2-
10	` /\ /	methoxybenzyl)ethanamine
11		Some trade or other names: 25D-NBOMe; 2C-D-NBOMe.
12	<del>(52)</del> (53)	2-(2,5-dimethoxy-4-nitrophenyl)-N-(2-methoxybenzyl)
13	( )( )	ethanamine
14		Some trade or other names: 25N-NBOMe, 2C-N-NBOMe.
15	(e) A	Any material, compound, mixture or preparation which contains
16		tity of the following substances having a depressant effect on the
17	central ne	ervous system, including its salts, isomers, and salts of isomers
18	whenever	the existence of such salts, isomers, and salts of isomers is
19		within the specific chemical designation:
20	(1)	Etizolam Some trade or other names: (4-(2-chlorophenyl)-2-
21	` '	ethyl-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a]
22		[1,4]diazepine)
23	(2)	Mecloqualone
24	<del>(2)</del> (3)	Methaqualone
25	$\frac{(3)}{(4)}$	Gamma hydroxybutyric acid
26	(f) U	Juless specifically excepted or unless listed in another schedule,
27	any mate	erial, compound, mixture or preparation which contains any
28	quantity	of the following substances having a stimulant effect on the
29	central ne	ervous system, including its salts, isomers and salts of isomers:
30	(1)	Aminorex 1585 some other names: Aminoxaphen 2-amino-5-
31		phenyl-2-oxazoline or 4,5-dihydro-5-phenyl-2-oxazolamine
32	(2)	Fenethylline
33	<del>(2)</del> (3)	N-ethylamphetamine1475
34	<del>(3)</del> (4)	(+)cis-4-methylaminorex ((+)cis-4,5-dihydro-4-methyl-5-
35		phenyl-2-oxazolamine)
36	(4)(5)	N,N-dimethylamphetamine (also known as N,N-alpha-
37		trimethyl-benzeneethanamine; N,N-alpha-
38		trimethylphenethylamine)1480
39	<del>(5)</del> (6)	Cathinone (some other names: 2-amino-1-phenol-1-propanone,
40		alpha-amino propiophenone, 2-amino propiophenone and
41		norphedrone)
42	<del>(6)</del> (7)	Substituted cathinones
43		Any compound, except bupropion or compounds listed under a

I		differe	ent schedule, structurally derived from 2–aminopropan–1–
2		one by	substitution at the 1-position with either phenyl,
3		naphtl	nyl, or thiophene ring systems, whether or not the
4		compo	ound is further modified in any of the following ways:
5		(A)	By substitution in the ring system to any extent with
6		` /	alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or
7			halide substituents, whether or not further substituted
8			in the ring system by one or more other univalent
9			substituents;
0		(B)	by substitution at the 3-position with an acyclic alkyl
11		. ,	substituent;
2		(C)	by substitution at the 2-amino nitrogen atom with
3			alkyl, dialkyl, benzyl, or methoxybenzyl groups; or
4		(D)	by inclusion of the 2-amino nitrogen atom in a cyclic
5		` ′	structure.
6	(g)	Any ma	terial, compound, mixture or preparation which contains
7			ne following substances:
8	(1)		penzyl-4-piperidyl]-N-phenylpropanamide
9	. ,		/Ifentanyl), its optical isomers, salts and salts of
20			ers
21	(2)		2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide
22	. ,		lfentanyl), its optical isomers, salts and salts of
23			rs
24 25	(3)	—Amino	orex (some other names: Aminoxaphen 2-amino-5-
25		pheny	1-2-oxazoline or 4,5-dihydro-5-phenyl-2-oxazolamine, its
26		salts, o	optical isomers and salts of optical isomers)1585
27	(4)	—Alpha	-ethyltryptamine, its optical isomers, salts and salts of
28		isome	rs 7249
29		Some	other names: etryptamine, alpha-methyl-1H-indole-3-
30		ethana	mine; 3-(2-aminobutyl) indole.
31			the following cannabinoids, their salts, isomers and salts
32	of isome	ers, unles	ss specifically excepted, whenever the existence of these
33	salts, isc	mers an	d salts of isomers is possible within the specific chemical
34	designat	ion:	
35	(1)	Tetrah	ydrocannabinols7370
36		Meani	ng tetrahydrocannabinols naturally contained in a plant of
37			nus Cannabis (cannabis plant), as well as synthetic
88		equiva	alents of the substances contained in the plant, or in the
39		resino	us extractives of Cannabis, sp. and/or synthetic
10		substa	nces, derivatives, and their isomers with similar chemical
11		structi	are and pharmacological activity such as the following:
12			1 cis or trans tetrahydrocannabinol, and their optical
13		isome	rs Delta 6 cis or trans tetrahydrocannabinol, and their

1		optical isomers Delta 3,4 cis or trans tetrahydrocannabinol, and
2		its optical isomers (Since nomenclature of these substances is
<i>3</i>		not internationally standardized, compounds of these structures, regardless of numerical designation of atomic positions
5		covered.)
6	(2)	Naphthoylindoles
7	(2)	
		Any compound containing a 3-(1-naphthoyl)indole structure
8		with substitution at the nitrogen atom of the indole ring by an
9		alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
l0		benzyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)
11		ethyl group, whether or not further substituted in the indole ring
12		to any extent and whether or not substituted in the <i>benzyl or</i>
13	(2)	naphthyl ring to any extent.
14	(3)	Naphthylmethylindoles
15		Any compound containing a 1H-indol-3-yl-(1-
16		naphthyl)methane structure with substitution at the nitrogen
17		atom of the indole ring by an alkyl, haloalkyl, alkenyl,
18		cycloalkylmethyl, cycloalkylethyl, <i>benzyl</i> , 1-(N-methyl-2-
19		piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or
20		not further substituted in the indole ring to any extent and
21		whether or not substituted in the <i>benzyl or</i> naphthyl ring to any
22	(4)	extent.
23	(4)	Naphthoylpyrroles 2 (1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
24		Any compound containing a 3-(1-naphthoyl)pyrrole structure
25		with substitution at the nitrogen atom of the pyrrole ring by an
26		alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
27		benzyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-
28		morpholinyl)ethyl group whether or not further substituted in
29		the pyrrole ring to any extent, whether or not substituted in the
30	(5)	benzyl or naphthyl ring to any extent.
31	(5)	Naphthylmethylindenes
32		Any compound containing a naphthylideneindene structure with
33		substitution at the 3-position of the indene ring by an alkyl,
34		haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, 1
35		(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl
36		group whether or not further substituted in the indene ring to
37		any extent, whether or not substituted in the <i>benzyl or</i> naphthyl
38	(6)	ring to any extent.
39	(6)	Phenylacetylindoles
40		Any compound containing a 3-phenylacetylindole structure
41 12		with substitution at the nitrogen atom of the indole ring by an
12 13		alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
ıή		penzyi 1-UN-meinyi-7-piperidinyi methyi or 7-14-

1 2		morpholinyl)ethyl group whether or not further substituted in the indole ring to any extent, whether or not substituted in the
3		benzyl or phenyl ring to any extent.
4	(7)	Cyclohexylphenols
5	( )	Any compound containing a 2-(3-hydroxycyclohexyl)phenol
6		structure with substitution at the 5-position of the phenolic ring
7		by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
8		cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-
9		morpholinyl)ethyl group whether or not substituted in the
10		cyclohexyl ring to any extent.
11	(8)	Benzoylindoles
12		Any compound containing a 3-(benzoyl)indole structure with
13		substitution at the nitrogen atom of the indole ring by an alkyl,
14		haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, 1-
15		(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl
16		group whether or not further substituted in the indole ring to
17		any extent and whether or not substituted in the benzyl or
18		phenyl ring to any extent.
19	(9)	2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-
20		de]-1,4-benzoxazin-6-yl]-1-napthalenylmethanone. Some trade
21		or other names: WIN 55,212-2.
22	(10)	9-(hydroxymethyl)-6, 6-dimethyl-3-(2-methyloctan-2-yl)-
23		6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
24		Some trade or other names: HU-210, HU-211.
25	(11)	Tetramethylcyclopropanoylindoles
26		Any compound containing a 3-tetramethylcyclopropanoylindole
27		structure with substitution at the nitrogen atom of the indole
28		ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl,
29		cycloalkylmethyl, cycloalkylethyl, benzyl, 1-(N-methyl-2-
30		piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
31		pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
32		tetrahydropyranylmethyl group, whether or not further
33		substituted in the indole ring to any extent and whether or not
34		substituted in the benzyl or tetramethylcyclopropyl rings to any
35	(1.5)	extent.
36	(12)	Indole-3-carboxylate esters
37		Any compound containing a 1H-indole-3-carboxylate ester
38		structure with the ester oxygen bearing a naphthyl, quinolinyl,
39		isoquinolinyl or adamantyl group and substitution at the 1
40		position of the indole ring by an alkyl, haloalkyl, alkenyl,
41		cycloalkylmethyl, cycloalkylethyl, benzyl, N-methyl-2-
42		piperidinylmethyl or 2-(4-morpholinyl)ethyl group, whether or
43		not further substituted on the indole ring to any extent and

(F)

1		whether or not substituted on the naphthyl, quinolinyl,
2		isoquinolinyl, adamantyl or benzyl groups to any extent.
3	(13)	Indazole-3-carboxamides
4		Any compound containing a 1H-indazole-3-carboxamide
5		structure with substitution at the nitrogen of the carboxamide by
6		a naphthyl, quinolinyl,isoquinolinyl, adamantyl, 1-amino-1-
7		oxoalkan-2-yl or 1-alkoxy-1-oxoalkan-2-yl group and
8		substitution at the 1 position of the indazole ring by an alkyl,
9		haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl,
10		N-methyl-2-piperidinylmethyl, or 2-(4-morpholinyl)ethyl
11		group, whether or not further substituted on the indazole ring to
12		any extent and whether or not substituted on the naphthyl,
13		quinolinyl,isoquinolinyl, adamantyl, 1-amino-1-oxoalkan-2-yl,
14		1-alkoxy-1-oxoalkan-2-yl or benzyl groups to any extent.
15	(14)	(1H-indazol-3-yl)methanones
16		Any compound containing a (1H-indazol-3-yl)methanone
17		structure with the carbonyl carbon bearing a naphthyl group and
18		substitution at the 1 position of the indazole ring by an alkyl,
19		haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl,
20		N-methyl-2-piperidinylmethyl, or 2-(4-morpholinyl)ethyl
21		group, whether or not further substituted on the indazole ring to
22		any extent and whether or not substituted on the naphthyl or
23	_	benzyl groups to any extent.
24		5. K.S.A. 2016 Supp. 65-4107 is hereby amended to read as
25		65-4107. (a) The controlled substances listed in this section are
26		in schedule II and the number set forth opposite each drug or
27		e is the DEA controlled substances code which has been assigned
28	to it.	
29		Any of the following substances, except those narcotic drugs
30		other schedules, whether produced directly or indirectly by
31		n from substances of vegetable origin or independently by means
32		ical synthesis or by combination of extraction and chemical
33	synthesis	
34	(1)	Opium and opiate and any salt, compound, derivative or
35	preparati	on of opium or opiate, excluding apomorphine, dextrorphan,
36 37		ne, nalmefene, naloxone and naltrexone and their respective salts,
		ding the following:
38		Raw opium 9600
39 40		Opium extracts
40 41		Powdered opium 9639
41		Granulated opium
4Z 43	(E)	Tineture of onium 9640

Tincture of opium......9630

1	(G)	Codeine	9050
2	(H)	Ethylmorphine	9190
3	(I)	Etorphine hydrochloride	9059
4	(J)	Hydrocodone	9193
5	(K)	Hydromorphone	
6	(L)	Metopon	9260
7	(M)	Morphine	9300
8	(N)	Oxycodone	
9	(O)	Oxymorphone	
10	(P)	Thebaine	9333
11	(Q)	Dihydroetorphine	9334
12	(R)	Oripavine	9330
13	(2)	Any salt, compound, isomer, derivative or preparat	tion thereof
14	which	is chemically equivalent or identical with any of the	substances
15		d to in paragraph (1), but not including the isoquinoline	
16	opium.		
17	(3)	Opium poppy and poppy straw.	
18	(4)	Coca leaves (9040) and any salt, compound, de	erivative or
19	prepara	ation of coca leaves, but not including decocainized coc	ca leaves or
20		ions which do not contain cocaine (9041) or ecgonine (9	
21	(5)	Cocaine, its salts, isomers and salts of isomers (9041).	,
22	(6)	Ecgonine, its salts, isomers and salts of isomers (9180)	
23	(7)	Concentrate of poppy straw (the crude extract of pop	
24	either	liquid, solid or powder form which contains the pl	
25		ds of the opium poppy) (9670).	
26	(c)		ners, esters,
27	ethers,	salts and salts of isomers, esters and ethers, whenever the	ne existence
28		e isomers, esters, ethers and salts is possible within	
29	chemic	al designation dextrorphan and levopropoxyphene excep	oted:
30	(1)	Alfentanil	9737
31	(2)	Alphaprodine	9010
32	(3)	Anileridine	
33	(4)	Bezitramide	9800
34	(5)	Bulk dextropropoxyphene (nondosage forms)	
35	(6)	Carfentanil	
36	(7)	Dihydrocodeine	9120
37	(8)	Diphenoxylate	9170
38	(9)	Fentanyl	9801
39	(10)	Isomethadone	
40	(11)	Levomethorphan	
41	(12)	Levorphanol	
42	(13)	Metazocine	
43	(14)	Methadone	

1	(15)	Methadone-intermediate,4-cyano-2-dimethyl amino-4,4-	
2	, ,	diphenyl butane	9254
3	(16)	Moramide-intermediate, 2-methyl-3-morpholino-1, 1-	
4	` /	diphenylpropane-carboxylic acid	9802
5	(17)	Pethidine (meperidine).	
6	(18)	Pethidine-intermediate-A, 4-cyano-1-methyl-4-	
7	,	phenylpiperidine	9232
8	(19)	Pethidine-intermediate-B, ethyl-4-phenyl-piperidine-4-	
9	,	carboxylate	9233
10	(20)	Pethidine-intermediate-C, 1-methyl-4-phenyl-piperidine-4	
11	,	carboxylic acid.	
12	(21)	Phenazocine	
13	(22)	Piminodine	9730
14	(23)	Racemethorphan	9732
15	(24)	Racemorphan	
16	(25)	Sufentanil	
17	(26)	Levo-alphacetyl methadol.	
18	,	Some other names: levo-alpha-acetyl methadol, levometha	adyl
19		acetate or LAAM.	3
20	(27)	Remifentanil	9739
21	(28)	Tapentadol	9780
22	(29)	Thiafentanil	
23	(d)	Any material, compound, mixture, or preparation which	contains
24	any qu	uantity of the following substances having a potential fo	r abuse
25	associa	ated with a stimulant effect on the central nervous system:	
26	(1)	Amphetamine, its salts, optical isomers and salts of its opt	ical
27	` ′	isomers	1100
28	(2)	Phenmetrazine and its salts	1631
29	(3)	Methamphetamine, including its salts, isomers and salts of	f
30		isomers	
31	(4)	Methylphenidate	1724
32	(5)	Lisdexamfetamine, its salts, isomers, and salts of its	
33	. ,	isomers	1205
34	(e)	Unless specifically excepted or unless listed in another so	chedule,
35	any m	naterial, compound, mixture or preparation which conta	ins any
36	quantit	ty of the following substances having a depressant effect	on the
37		nervous system, including its salts, isomers and salts of	
38	whene	ver the existence of such salts, isomers and salts of iso	mers is
39	possib	le within the specific chemical designation:	
40	(1)	Amobarbital	2125
41	(2)	Glutethimide	2550
42	(3)	Secobarbital	2315
43	(4)	Pentobarbital	2270

40

41

42

43

1	(5) Phencyclidine/4/1
2	(f) Any material, compound, mixture, or preparation which contains
3	any quantity of the following substances:
4	(1) Immediate precursor to amphetamine and methamphetamine:
5	(A) Phenylacetone8501
6	Some trade or other names: phenyl-2-propanone; P2P; benzyl
7	methyl ketone; methyl benzyl ketone.
8	(2) Immediate precursors to phencyclidine (PCP):
9	(A) 1-phenylcyclohexylamine7460
10	(B) 1-piperidinocyclohexanecarbonitrile (PCC)8603
11	(g) Any material, compound, mixture or preparation which contains
12	any quantity of the following hallucinogenic substance, its salts, isomers
13	and salts of isomers, unless specifically excepted, whenever the existence
14	of these salts, isomers and salts of isomers is possible within the specific
15	chemical designation:
16	Nabilone
17	[Another name for nabilone: (±)-trans-3-(1,1-dimethylheptyl)-
18	6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-9H-
19	dibenzo[b,d]pyran-9-one]
20	(h) Any material, compound, mixture or preparation containing any
21	of the following narcotic drugs or any salts calculated as the free
22	anhydrous base or alkaloid, in limited quantities as set forth below:
23	(1) Not more than 300 milligrams of dihydrocodeinone (hydrocodone) or
24	any of its salts per 100 milliliters or not more than 15 milligrams
25	per dosage unit with a fourfold or greater quantity of an
26	isoquinoline alkaloid of opium9805
27	(2) Not more than 300 milligrams of dihydrocodeinone (hydrocodone) or
28	any of its salts per 100 milliliters or not more than 15 milligrams
29	per dosage unit with one or more active, nonnarcotic ingredients
30	in recognized therapeutic amounts9806
31	Sec. 6. K.S.A. 2016 Supp. 65-4113 is hereby amended to read as
32	follows: 65-4113. (a) The controlled substances or drugs, by whatever
33	official name, common or usual name, chemical name or brand name
34	designated, listed in this section are included in schedule V.
35	(b) Any compound, mixture or preparation containing limited
36	quantities of any of the following narcotic drugs which also contains one
37	or more nonnarcotic active medicinal ingredients in sufficient proportion
38	to confer upon the compound, mixture or preparation valuable medicinal

(1) Not more than 200 milligrams of codeine or any of its salts per 100 milliliters or per 100 grams.

qualities other than those possessed by the narcotic drug alone:

(2) Not more than 100 milligrams of dihydrocodeine or any of its salts per 100 milliliters or per 100 grams.

- (3) Not more than 100 milligrams of ethylmorphine or any of its salts per 100 milliliters or per 100 grams.
- (4) Not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage unit.
- (5) Not more than 100 milligrams of opium per 100 milliliters or per 100 grams.
- (6) Not more than .5 milligram of difenoxin (9168) and not less than 25 micrograms of atropine sulfate per dosage unit.
- (c) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position or geometric) and salts of such isomers whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation:
- (1) Propylhexedrine (except when part of a compound used for nasal decongestion which is authorized to be sold lawfully over the counter without a prescription under the federal food, drug and cosmetic act, so long as it is used only for such

- (d) Any compound, mixture or preparation containing any detectable quantity of ephedrine, its salts or optical isomers, or salts of optical isomers.
- (e) Any compound, mixture or preparation containing any detectable quantity of pseudoephedrine, its salts or optical isomers, or salts of optical isomers.
- (f) Unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts:

- 39 (3)(4) Pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic acid]...2782 40 Sec. 7. K.S.A. 2016 Supp. 21-5701, 65-4101, 65-4102, 65-4105, 65-
- 40 Sec. 7. K.S.A. 2016 Supp. 21-5701, 65-4101, 65-4102, 65-4105, 65-4107 and 65-4113 are hereby repealed.
- Sec. 8. This act shall take effect and be in force from and after its publication in the Kansas register.